Loading…
Employees: 43
Size AP Biosciences (6945.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $330M, the 614th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$112.00 on 6 Nov 2026.
Performance Over six months the shares fell 32.3%, against -22.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th lowest of 18 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +7.4%).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$0 | NT$0 | NT$0 | NT$32.3M | NT$0 |
| Revenue growth | — | — | -100% | — | — |
| Gross profit | -NT$28.7M | -NT$25.5M | -NT$17.5M | n/a | -NT$8.68M |
| EBITDA | -NT$489M | -NT$431M | -NT$422M | -NT$335M | -NT$289M |
| Net income | -NT$464M | -NT$445M | -NT$423M | -NT$339M | -NT$289M |
| Free cash flow | n/a | -NT$377M | -NT$363M | -NT$333M | -NT$277M |
| Capital expenditure | n/a | NT$25.3M | NT$5.53M | NT$35.4M | NT$2.43M |
| Total debt | NT$53.7M | NT$59.5M | NT$70.9M | NT$82.1M | NT$0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6945.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.5% | -11.3% | 10th lowest of 20 |
| 6-month return | -32.3% | -22.3% | 7th lowest of 18 |
| Distance from 52-week high | -52.5% | -53.3% | 10th highest of 20 |
| Revenue growth (TTM) | -100.0% | +7.4% | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | 4.8× | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | 9.9× | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | 36.4× | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | 4.4× | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | 11.6× | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $310M | -39% | +7% | 7% | 2.0× | 6.0% | +11.9% |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | n/a | n/a | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Circio CRNA.OL | Norway | $303M | -14% | n/a | n/a | n/a | n/a | n/a |
| Kyverna Therapeutics KYTX | United States | $302M | -48% | n/a | n/a | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |